Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme
Safety data reported in the real-world SURE studies were generally consistent with observations in phase 3 OW semaglutide RCTs. No new safety concerns were identified, highlighting that OW semaglutide is well tolerated by adults with T2D and in subpopulations in routine clinical practice.
Authors
- Markus Menzen (ORCID: https://orcid.org/0000-0002-1773-4591)
- Andrei‐Mircea Catarig (ORCID: https://orcid.org/0000-0002-7667-8315)
- Rashmi Jain (ORCID: https://orcid.org/0000-0001-6422-5143)
- Jean‐François Yale (ORCID: https://orcid.org/0000-0002-7833-9050)
- Patrick Holmes (ORCID: https://orcid.org/0000-0002-6401-663X)
- Atheline Major‐Pedersen (ORCID: https://orcid.org/0000-0002-1755-630X)
Institutions
- St George's Hospital (GB)
- Novo Nordisk (Denmark) (DK)
- McGill University Health Centre (CA)
- Gemeinschaftskrankenhaus Havelhöhe (DE)
- Novo Nordisk (India) (IN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-08-08
- DOI
- https://doi.org/10.1111/dom.15794
- Citations
- 13
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 4.65
Funders
- Novo Nordisk